Why Is Buffett Buying Verisign?
Warren Buffett has spent 2024 stockpiling cash, even going so…
Sell
33
INSP Quote, Financials, Valuation and Earnings
Last price:
$186.19
Seasonality move
:
2.85%
Day range:
$184.51 - $190.32
52-week range:
$123.00 - $257.40
Dividend yield:
0%
P/E ratio:
176.15x
P/S ratio:
7.49x
P/B ratio:
8.11x
Volume:
231.1K
Avg. volume:
458.6K
1-year change:
-7.37%
Market cap:
$5.6B
Revenue:
$624.8M
EPS (TTM):
$1.07
Analysts' Opinion
-
Consensus RatingInspire Medical Systems has received a consensus rating of Buy. The company's average rating is a Buy based on 8 Buy ratings, 4 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $239.60, Inspire Medical Systems has an estimated upside of 27.12% from its current price of $188.48.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $193.00 representing 100% downside risk from its current price of $188.48.
Fair Value
-
According to the consensus of 12 analysts, Inspire Medical Systems has 27.12% upside to fair value with a price target of $239.60 per share.
INSP vs. S&P 500
-
Over the past 5 trading days, Inspire Medical Systems has overperformed the S&P 500 by 0.97% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Inspire Medical Systems does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Inspire Medical Systems has grown year-over-year revenues for 17 quarters straight. In the most recent quarter Inspire Medical Systems reported revenues of $203.2M.
Earnings Growth
-
Inspire Medical Systems has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Inspire Medical Systems reported earnings per share of $0.60.
Enterprise value:
5.2B
EV / Invested capital:
7.52x
Price / LTM sales:
7.49x
EV / EBIT:
154.67x
EV / Revenue:
6.93x
PEG ratio (5yr expected):
--
EV / Free cash flow:
137.09x
Price / Operating cash flow:
148.23x
Enterprise value / EBITDA:
135.15x
Gross Profit (TTM):
$640.5M
Return On Assets:
4.69%
Net Income Margin (TTM):
4.37%
Return On Equity:
5.44%
Return On Invested Capital:
5.44%
Operating Margin:
7.05%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Income Statement | ||||||
| Revenue | $348.4M | $570.2M | $755.6M | $153.3M | $203.2M | |
| Gross Profit | $293.2M | $479.5M | $640.5M | $128.9M | $170.8M | |
| Operating Income | -$49.1M | -$49.9M | $13.5M | -$13.5M | $14.3M | |
| EBITDA | -$46.1M | -$43.7M | $38.8M | -$12.7M | $16.2M | |
| Diluted EPS | -$1.83 | -$1.13 | $1.07 | -$0.29 | $0.60 | |
| Period Ending | 2020-09-30 | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $266.9M | $255.5M | $495.5M | $569.6M | $582.5M | |
| Total Assets | $271.8M | $278.9M | $527.5M | $639.5M | $796.2M | |
| Current Liabilities | $18.2M | $33.6M | $49.3M | $70M | $74.3M | |
| Total Liabilities | $43M | $58.6M | $57.3M | $95.3M | $99.6M | |
| Total Equity | $228.8M | $220.3M | $470.2M | $544.2M | $696.6M | |
| Total Debt | $24.7M | $24.9M | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2023-09-30 | 2024-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7M | $26.7M | $78.3M | $3.6M | $52.3M | |
| Cash From Investing | -$17.2M | -$146M | -$268.6M | -$144.2M | -$103M | |
| Cash From Financing | $231.9M | $31.4M | $7.6M | $3.5M | $9.9M | |
| Free Cash Flow | -$13.6M | $8.1M | $38.2M | -$3.4M | $44.3M | |
INSP
Sector
Market Cap
$5.6B
$45.9M
Price % of 52-Week High
73.23%
46.95%
Dividend Yield
0%
0%
Shareholder Yield
--
-0.6%
1-Year Price Total Return
-7.37%
-32.15%
Beta (5-Year)
1.313
0.772
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Technicals
8-day SMA
Buy
Level
$187.79
200-day SMA
Buy
Level
$186.53
Bollinger Bands (100)
Sell
Level
183.93 - 206.17
Chaikin Money Flow
Buy
Level
4.5M
20-day SMA
Sell
Level
$189.77
Relative Strength Index (RSI14)
Sell
Level
48.50
ADX Line
Sell
Level
17.27
Williams %R
Neutral
Level
-51.5041
50-day SMA
Sell
Level
$191.36
MACD (12, 26)
Sell
Level
-1.07
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
18.7M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (35.6202)
Buy
CA Score
(Annual)
Level (1.441)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (7)
Buy
Ohlson Score
Level (-1.3688)
Buy
Piotroski F Score
(Annual)
Level (7)
Buy
Quality Ratio Score
Level (7)
Buy
Fundamental Score
Level (5)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Inspire Medical Systems Inc operates as a medical technology company. It focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA). It offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe obstructive sleep apnea. The firm has operating footprints in the United States and Europe wherein, it generates a majority of its revenue from the United States.
Stock Forecast FAQ
In the current month, INSP has received 8 Buy ratings 4 Hold ratings, and 0 Sell ratings. The INSP average analyst price target in the past 3 months is $239.60.
-
Where Will Inspire Medical Systems Stock Be In 1 Year?
According to analysts, the consensus estimate is that Inspire Medical Systems share price will rise to $239.60 per share over the next 12 months.
-
What Do Analysts Say About Inspire Medical Systems?
Analysts are divided on their view about Inspire Medical Systems share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Inspire Medical Systems is a Sell and believe this share price will drop from its current level to $193.00.
-
What Is Inspire Medical Systems's Price Target?
The price target for Inspire Medical Systems over the next 1-year time period is forecast to be $239.60 according to 12 Wall Street analysts, 8 of them rate the stock a Buy, 0 rate the stock a Sell, and 4 analysts rate the stock a Hold.
-
Is INSP A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Inspire Medical Systems is a Buy. 8 of 12 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of INSP?
You can purchase shares of Inspire Medical Systems via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, TastyTrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Inspire Medical Systems shares.
-
What Is The Inspire Medical Systems Share Price Today?
Inspire Medical Systems was last trading at $186.19 per share. This represents the most recent stock quote for Inspire Medical Systems. Yesterday, Inspire Medical Systems closed at $188.48 per share.
-
How To Buy Inspire Medical Systems Stock Online?
In order to purchase Inspire Medical Systems stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Related Companies
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Is Microsoft an Undervalued Growth Stock to Buy?
Tech giant Microsoft (NASDAQ:MSFT) has been one of the biggest…
Will Tesla Go Up or Down in 2025?
The last few months have been exciting for Tesla and…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.9T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.4T
P/E Ratio: 115x
Buy
54
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 36x
Alerts
Sell
50
LMND alert for Dec 30
Lemonade [LMND] is down 2.82% over the past day.
Buy
63
SMLR alert for Dec 30
Semler Scientific [SMLR] is down 11.17% over the past day.
Sell
39
DOGZ alert for Dec 30
Dogness (International) [DOGZ] is up 3.61% over the past day.
